MX2015009154A - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Info

Publication number
MX2015009154A
MX2015009154A MX2015009154A MX2015009154A MX2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A
Authority
MX
Mexico
Prior art keywords
narcolepsy
treatment
receptor agonists
alpha
nicotinic receptor
Prior art date
Application number
MX2015009154A
Other languages
English (en)
Other versions
MX362819B (es
Inventor
Baltazar Gomez-Mancilla
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009154A publication Critical patent/MX2015009154A/es
Publication of MX362819B publication Critical patent/MX362819B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere al uso de ciertos agonistas del receptor nicotínico de acetilcolina alfa 7 para uso en el tratamiento, mejora, prevención o retraso del avance de la narcolepsia, la somnolencia excesiva durante el día, la perturbación del sueño nocturno y/o la cataplexia.
MX2015009154A 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. MX362819B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/050368 WO2014111751A1 (en) 2013-01-15 2013-01-15 Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy

Publications (2)

Publication Number Publication Date
MX2015009154A true MX2015009154A (es) 2016-03-04
MX362819B MX362819B (es) 2019-02-18

Family

ID=47747729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009154A MX362819B (es) 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Country Status (9)

Country Link
EP (1) EP2945626B1 (es)
JP (1) JP6137336B2 (es)
KR (1) KR101879921B1 (es)
CN (1) CN105263492B (es)
BR (1) BR112015016994A8 (es)
CA (1) CA2898043C (es)
ES (1) ES2701083T3 (es)
MX (1) MX362819B (es)
WO (1) WO2014111751A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689863A1 (en) * 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
AU2003250322B2 (en) * 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
SK288115B6 (sk) 2002-09-25 2013-09-03 Memory Pharmaceuticals Corporation Indazoles, pharmaceutical compositions comprising them and their use
EP1677789A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
CA2549965A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
JP2007509935A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズｉｉ
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
AR049401A1 (es) * 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008538417A (ja) 2005-04-08 2008-10-23 エクステラス インコーポレイテッド 多重チャンネル波長分散補償器
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
MY147661A (en) 2006-05-19 2012-12-31 Abbott Lab Fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
WO2010043515A1 (en) 2008-10-13 2010-04-22 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia

Also Published As

Publication number Publication date
WO2014111751A1 (en) 2014-07-24
MX362819B (es) 2019-02-18
CN105263492A (zh) 2016-01-20
EP2945626B1 (en) 2018-09-12
JP2016504407A (ja) 2016-02-12
JP6137336B2 (ja) 2017-05-31
BR112015016994A2 (pt) 2017-07-11
EP2945626A1 (en) 2015-11-25
CN105263492B (zh) 2018-04-10
BR112015016994A8 (pt) 2018-01-23
CA2898043A1 (en) 2014-07-24
ES2701083T3 (es) 2019-02-20
KR101879921B1 (ko) 2018-07-18
KR20150104632A (ko) 2015-09-15
CA2898043C (en) 2019-08-06

Similar Documents

Publication Publication Date Title
EP3630072A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
SG10201913054TA (en) Novel lactobacillus having various functions, and use thereof
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
EP3068289A4 (en) Prevention and treatment of bed exits, falls, and other conditions
ZA201903934B (en) Novel tnfr agonists and uses thereof
BR112017006664A2 (pt) terapias de combinação
PH12015502788A1 (en) Antibody formulations and methods
EP2967978A4 (en) DEVICES, SYSTEMS AND METHOD FOR COOLING THE SKIN
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
HK1250469A1 (zh) 內窺鏡系統、裝置和方法
EP2999421A4 (en) CRYOGENIC TREATMENT SYSTEMS
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
ZA201705254B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
PL3274388T3 (pl) Urządzenia z akustyczną i termiczną izolacją na bazie lepkosprężystego poliuretanu
AU363883S (en) Tracking device
HK1249851A1 (zh) 使用聚維酮碘的普通感冒的治療和預防
EP2961420A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING BARTH SYNDROME
ZA201705222B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX362819B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
IL257452B (en) Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
EP3228677A4 (en) Friction resistance reducing agent and fire-extinguishing agent

Legal Events

Date Code Title Description
FG Grant or registration